DK184890A - Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme - Google Patents
Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme Download PDFInfo
- Publication number
- DK184890A DK184890A DK184890A DK184890A DK184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A DK 184890 A DK184890 A DK 184890A
- Authority
- DK
- Denmark
- Prior art keywords
- immunotoxin
- auto
- cell
- preparation
- treatment
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
- 229940051026 immunotoxin Drugs 0.000 title 1
- 239000002596 immunotoxin Substances 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15174488A | 1988-02-03 | 1988-02-03 | |
| PCT/US1989/000440 WO1989006968A1 (en) | 1988-02-03 | 1989-02-03 | Therapeutic use of anti-t cell immunotoxin for autoimmune diseases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK184890D0 DK184890D0 (da) | 1990-08-02 |
| DK184890A true DK184890A (da) | 1990-10-03 |
Family
ID=22540082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK184890A DK184890A (da) | 1988-02-03 | 1990-08-02 | Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0397798A4 (da) |
| JP (1) | JPH03503887A (da) |
| AU (1) | AU633251B2 (da) |
| DK (1) | DK184890A (da) |
| WO (1) | WO1989006968A1 (da) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0419462A4 (en) * | 1987-07-17 | 1991-07-17 | Xoma Corporation | Improved immunotoxin therapies utilizing purified ricin a-chain species |
| US6001360A (en) * | 1988-12-13 | 1999-12-14 | University Of Florida | Method and compositions for early detection and treatment of insulin dependent diabetes mellitus |
| US5762937A (en) * | 1988-12-13 | 1998-06-09 | University Of Florida Research Foundation, Inc. | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
| EP0448635B1 (en) * | 1988-12-13 | 1995-09-20 | University Of Florida | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
| US5645998A (en) | 1988-12-13 | 1997-07-08 | University Of Florida Research Foundation | Methods and compositions for the early detection and treatment of insulin dependent diabetes mellitus |
| JPH04504173A (ja) * | 1989-03-06 | 1992-07-23 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 免疫吸着剤のアッセイおよび処置 |
| US5397702A (en) * | 1989-03-06 | 1995-03-14 | The Regents Of The University Of California | Assay for and treatment of autoimmune diseases |
| US6113903A (en) * | 1989-03-21 | 2000-09-05 | The Immune Response Corporation | Peptides and methods against diabetes |
| IL98932A0 (en) * | 1990-07-27 | 1992-07-15 | Univ California | Assay,kits and methods based on nk+channel expression |
| IT1249051B (it) * | 1991-02-26 | 1995-02-11 | Italfarmaco Spa | Immunotossina da anticorpi monoclonali anti-cd5 |
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| US5837491A (en) * | 1991-11-04 | 1998-11-17 | Xoma Corporation | Polynucleotides encoding gelonin sequences |
| US6146850A (en) * | 1991-11-04 | 2000-11-14 | Xoma Corporation | Proteins encoding gelonin sequences |
| CA2507749C (en) * | 1991-12-13 | 2010-08-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| AUPN115095A0 (en) * | 1995-02-15 | 1995-03-09 | Butt, Henry Lawrence | Analysis of and compositions and methods for the treatment of disease |
| US7288254B2 (en) | 1995-10-30 | 2007-10-30 | The United States Of America As Represented By The Secretary, Department Of Health And Human Services, Nih | Use of immunotoxins to induce immune tolerance to pancreatic islet transplantation |
| US7696338B2 (en) | 1995-10-30 | 2010-04-13 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin fusion proteins and means for expression thereof |
| US7517527B2 (en) | 1995-10-30 | 2009-04-14 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin with in vivo T cell suppressant activity and methods of use |
| DE69840913D1 (de) | 1997-03-05 | 2009-07-30 | Us Health | Divalent anti-t-zellen immuntoxinen und deren verwendung |
| DE69941182D1 (de) * | 1998-04-22 | 2009-09-10 | Uab Research Foundation | Verwendung von immunotoxinen zur auslösung einer immuntoleranz bei transplantation der inselzellen der bauchspeicheldrüse |
| WO2006115509A2 (en) | 2004-06-24 | 2006-11-02 | Novartis Vaccines And Diagnostics Inc. | Small molecule immunopotentiators and assays for their detection |
| GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
| CA3082310A1 (en) | 2017-11-29 | 2019-06-06 | Magenta Therapeutics, Inc. | Compositions and methods for the depletion of cd5+ cells |
| CN114206358A (zh) * | 2019-06-05 | 2022-03-18 | 美真达治疗公司 | T细胞消耗疗法 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4590071A (en) * | 1984-09-25 | 1986-05-20 | Xoma Corporation | Human melanoma specific immunotoxins |
| EP0232447A1 (en) * | 1986-02-13 | 1987-08-19 | Xoma Corporation | Lectin immunotoxins |
| US4731244A (en) * | 1985-11-13 | 1988-03-15 | Ortho Pharmaceutical Corporation | Monoclonal antibody therapy |
| EP0256471A3 (en) * | 1986-08-15 | 1989-10-25 | Xoma Corporation | Cytotoxic conjugates for cancer therapy |
| ATE137119T1 (de) * | 1987-08-17 | 1996-05-15 | Us Commerce | Verfahren zur behandlung der bösartigen und autoimmunen krankheiten beim menschen |
| US5004692A (en) * | 1987-12-15 | 1991-04-02 | Protein Design Labs, Inc. | Cloning and expression of phosopholipase C genes |
| JPH03503164A (ja) * | 1988-02-03 | 1991-07-18 | エクソウマ コーポレーション | 抗‐パンｔ‐細胞イムノトキシン組成物による免疫抑制 |
-
1989
- 1989-02-03 AU AU32157/89A patent/AU633251B2/en not_active Ceased
- 1989-02-03 WO PCT/US1989/000440 patent/WO1989006968A1/en not_active Ceased
- 1989-02-03 EP EP19890902872 patent/EP0397798A4/en not_active Withdrawn
- 1989-02-03 JP JP1502664A patent/JPH03503887A/ja active Pending
-
1990
- 1990-08-02 DK DK184890A patent/DK184890A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU3215789A (en) | 1989-08-25 |
| EP0397798A4 (en) | 1991-10-30 |
| DK184890D0 (da) | 1990-08-02 |
| JPH03503887A (ja) | 1991-08-29 |
| EP0397798A1 (en) | 1990-11-22 |
| WO1989006968A1 (en) | 1989-08-10 |
| AU633251B2 (en) | 1993-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK184890D0 (da) | Anvendelse af anti-t-celle-immunotoxin til fremstilling af farmaceutiske praeparater til behandling af autoimmune sygdomme | |
| DK215987D0 (da) | Farmaceutiske praeparater af syrelabile stoffer tiloral indgift | |
| DK362189A (da) | Farmaceutisk praeparat til intravenoes indgift | |
| NO922005D0 (no) | Farmasoeytiske preparater | |
| DK333788A (da) | Farmaceutisk praeparat til behandling af oedelagt bruskvaev | |
| DK263288D0 (da) | Farmaceutisk praeparat af cefuroxim-axetil | |
| DK149988D0 (da) | Stabile farmaceutiske praeparater | |
| DK184087A (da) | Farmaceutiske praeparater med forbedret biotilgaengelighed | |
| DK413987D0 (da) | Farmaceutiske praeparater | |
| NO872551D0 (no) | Fremgangsmaate for fremstilling av farmasoeytiske preparater | |
| DK397388A (da) | Derivater af n-aminobutyl-n-phenylarylamider til terapeutisk anvendelse samt fremgangsmaade til fremstilling af saadanne derivater | |
| FI913100A7 (fi) | Farmaseuttiset valmisteet | |
| DK652787D0 (da) | Farmaceutiske praeparater | |
| DK226488D0 (da) | Anvendelse af ace-inhibitorer til fremstilling af farmaceutiske praeparater | |
| NO874200L (no) | Fremgangsmaate for fremstilling av farmasoeytiske preparater | |
| DK635988A (da) | 1,3-butandiolacetoacetat-derivater og anvendelse af 1,3-butandiolacetoacetat-forbindelser til fremstilling af farmaceutiske praeparater | |
| DK298389D0 (da) | Farmaceutisk praeparat til topisk anvendelse omfattende et amin-funktionelt medikament | |
| DK447887A (da) | Frysetoerrede farmaceutiske praeparater | |
| DK0458855T3 (da) | Farmaceutisk præparat til behandling af tonsillitis | |
| NO873423D0 (no) | Fremgangsmaate for fremstilling av farmasoeytiske preparater | |
| NO875359D0 (no) | Fremgangsmaate for fremstilling av farmasoeytiske preparater | |
| NO872233D0 (no) | Fremgangsmaate for fremstilling av farmasoeytiske preparater | |
| DK500589A (da) | Farmaceutisk praeparat til behandling af lungeobstruktioner | |
| DK701588A (da) | N-hydroxy-5-phenyl-2-furancarboximidamider og anvendelse heraf til fremstilling af farmceutiske praeparater | |
| NO883663L (no) | Fremgangsmaate for fremstilling av farmasoeytiske preparater |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AHB | Application shelved due to non-payment |